Skip to main
MNOV
MNOV logo

MediciNova (MNOV) Stock Forecast & Price Target

MediciNova (MNOV) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MediciNova Inc. demonstrates a strong potential for stock performance due to its expanding therapeutic indications for MN-001, which could extend beyond hepatic fibrosis into metabolic and cardiovascular diseases, highlighting the drug's unique properties in lipid regulation and fibrosis modulation. Moreover, the company's progress in advancing the neurology pipeline, particularly with MN-166 (ibudilast) through the completion of patient enrollment in the COMBAT-ALS Phase 3 study, underpins its commitment to addressing critical neurological disorders. Additionally, positive preclinical findings regarding MN-002's role in cholesterol clearance further solidify MediciNova's positioning in the atherosclerosis and metabolic disease sectors, potentially enhancing its therapeutic portfolio ahead of anticipated topline data release in summer 2026.

Bears say

MediciNova Inc's financial outlook remains concerning due to its narrow focus on developing therapeutics in niche markets, which may limit revenue opportunities and market scalability. The company has been experiencing high research and development expenses without a corresponding increase in product pipeline advancements or clinical trial successes, raising concerns about long-term sustainability. Additionally, the lack of diversification in its therapeutic portfolio may expose the firm to higher risks associated with regulatory approvals and market competition, further compounding its negative financial trajectory.

MediciNova (MNOV) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MediciNova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MediciNova (MNOV) Forecast

Analysts have given MediciNova (MNOV) a Strong Buy based on their latest research and market trends.

According to 2 analysts, MediciNova (MNOV) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MediciNova (MNOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.